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Polypharmacy is very common in older adults and increases the risk of inappropriate and unsafe prescribing for 
older adults. Older adults, particularly women (who make up the majority of this age group), are at the greatest 
risk for drug-related harm. Therefore, optimising drug prescribing for older people is very important. Identifying 
potentially inappropriate medications and opportunities for judicious deprescribing processes are intrinsically 
linked, complementary, and essential for optimising medication safety. This Review focuses on optimising 
prescribing for older adults by reducing doses or stopping drugs that are potentially harmful or that are no longer 
needed. We explore how sex (biological) and gender (sociocultural) factors are important considerations in safe 
drug prescribing. We conclude by providing a practical approach to optimising medication safety that clinicians 
can routinely apply to the care of their older patients, highlighting how sex and gender considerations inform 
medication decision making.
Introduction 
The global population is aging rapidly. Many countries 
are now super-aged societies where more than 20% of 
their population are older than 65 years.1 Women 
comprise the majority of the older population, a 
percentage that increases with advancing age.2 Older 
adults are at greatest risk for drug-related harm. Older 
women might be more susceptible to drug-related 
harm than older men, which is due, in part, to 
pharmacokinetic and pharmacodynamic changes,3 
making medication optimisation for older women 
particularly important.
If done carefully and systematically, reducing drug 
doses, stopping inappropriate drug therapies, and 
choosing alternative safer therapies can improve the 
quality of life for many older people. Realising the 
widespread scale of harm arising from polypharmacy, 
WHO identified Medication Without Harm as the third 
international Global Patient Safety Challenge.4 This 
initiative, designed to raise global awareness about 
inappropriate and hazardous prescribing, was 
launched in 2017 and aims to reduce avoidable 
medication harm by 50% globally over 5 years. Depre-
scribing potentially inappropriate medications can 
mini mise drug-related harm for older adults, 
particularly women. Proper medication management 
requires attention on an international scale, now more 
than ever.
This Review focuses on optimising prescribing for 
older adults by reducing doses of certain drugs or 
stopping drugs that are no longer needed. Although we 
focus on high-income countries, what we describe 
should be relevant worldwide. Throughout this 
Review, we explore how sex (biological) and gender 
(sociocultural) factors are important considerations in 
safe medication prescribing and deprescribing for older 
adults. We conclude by providing a practical approach 
to medication review and management that clinicians 
can routinely apply to the care of individual older 
patients.
Problems with the way that drug therapies are 
prescribed 
A series of problems with the way that pharmaco-
therapeutic decisions are made and implemented 
contribute to polypharmacy, inappropriate medication 
prescribing, and the need for deprescribing. When 
making treatment decisions, physicians often do not 
consider non-pharmacological approaches as a first step. 
The benefit of implementing good sleep hygiene to 
improve sleep5 instead of prescribing a sleep aid is an 
example of a non-pharmacological approach, which can 
be very effective but is under-used.6 In a retrospective 
cohort study done in community-dwelling older adults, 
one in five participants with a new sleep disorder 
diagnosis were prescribed a medication for sleep, and a 
higher proportion were women.7 Further, prescribing 
guidance is generally based on what is appropriate for 
a single medical condition, without taking into 
consideration that two-thirds of adults older than 
65 years have multiple chronic conditions requiring the 
use of numerous medications. Following prescribing 
guide lines for each medical condition separately might 
result in medications being prescribed that place an 
older adult at an increased risk for drug interactions and 
other adverse events.8 Additionally, evidence shows that 
prescribing practices for antibiotic therapy among 
nursing home residents with advanced dementia do not 
routinely take into consideration an individual’s goals of 
care or their remaining life expectancy.9 Important 
factors such as an individual’s cognitive status and 
whether they are frail are insufficiently considered when 
assessing the potential benefit of a medication.10 Further, 
drug therapies are often generally added but seldom 
stopped.11 Drug prescribing texts and online resources 
do not routinely provide information about judicious 
stopping of drug therapies. Finally, and perhaps most 
important, drug prescribing takes a holistic approach 
that generally does not consider important biological 
and sociocultural differences between women and men. 
Given that the majority of older people are women, and 
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women are more vulnerable than men to drug-related 
harm, it is important to consider sex and gender 
differences when striving to optimise drug prescribing.
Applying a sex and gender lens to drug therapy 
The importance of considering sex and gender has been 
highlighted in the recent Lancet Series on sex and 
gender12 and in a review on sex and gender as modifiers 
of health and disease and medicine.13 Women and men 
respond to drug therapies differently; therefore, when 
sex and gender differences are not considered, women 
are placed at greater risk of medication-related harm.3 
Yet, this fundamental information is noteworthy for its 
absence in the medical literature.13 The scarcity of 
information about differences between older women and 
men in regards to the effects of drug therapies can be 
largely traced back to their under-representation in 
clinical trials. It was not until 1993 that the US National 
Institutes of Health (NIH) established guidelines for the 
inclusion of women and minority groups in NIH-funded 
clinical research through the NIH Revitalization Act 
of 1993.14 Notably, this directive focused on women in 
general. Although it might be assumed that older women 
should be a key group, considering that they are the 
largest consumers of medications in most countries, the 
intersection of sex and age was not highlighted in the 
NIH Revitalization Act. In 2019, the NIH Inclusion 
Across the Lifespan policy15 was implemented to help 
address the inadequate inclusion of older adults in NIH-
funded studies; the policy also required that study 
enrolment reporting had to be done on the sex, gender, 
age, and race of participants.16 When policies focus 
separately on these characteristics, the identification of 
older women might be missed.13 Additionally, despite 
these initiatives, older adults continue to be under-
represented in clinical trials, due to implicit exclusion 
based on comorbidities, function, or cognitive status that 
disproportionately affects older adults.17,18
The drug therapies prescribed to men and women often 
differ, and these prescribing decisions are not always 
aligned with evidence. For example, women are more 
likely to be prescribed medications for the management of 
conditions, including migraine, thyroid disorders, 
depression, and sleeping problems.19 However, men are 
more likely to be prescribed secondary prevention therapy, 
particularly for heart disease.20,21 There is also evidence 
that women are at greater risk for adverse drug-related 
events than men.19,22,23 In 2001, the General Accounting 
Office evaluated the prescription drugs that were 
withdrawn from the market in the USA.24 Of the 10 drug 
therapies withdrawn, eight were withdrawn due to greater 
risks to women than men. Another example is zolpidem, 
a non-benzodiazepine hypnotic that is widely used for 
insomnia, which illustrates that women might be more 
likely than men to need a lower dose of a drug therapy due 
to sex-based pharmacokinetic and pharmacodynamic 
differences.25 In 2011, in the USA, about 39 million 
prescriptions of zolpidem were dispensed nationally and 
63% of these were to women.25 After being on the market 
for more than 20 years, data showed that the risk of next-
morning drowsiness from zolpidem—enough to impair 
driving ability—was greater in women than in men 
receiving the same doses.25 There are important 
pharmacokinetic differences associated with sex; the 
clearance rate of zolpidem is 40–50% lower in females 
than males.26 As a result, the Food and Drug Administration 
recommended that the zolpidem dose for women should 
be reduced by half.25 Older adults also have lower clearance 
rates of drugs leading to higher concentrations relative to 
younger adults. This information is seldom presented in a 
sex-disaggregated and age-disaggregated manner that 
would be particularly helpful to guide prescribing for 
individuals who are women and who are also older. There 
are also instances in which men might be more affected 
by a drug therapy than women. This situation has been 
shown by the presentation of serious events after the use 
of atypical and typical antipsychotic therapy, in which men 
had more serious events than women.27
Gender-related sociocultural factors might also 
influence the decision to stop a medication. For example, 
gender might influence the ability to pay for a medication. 
Paying for costly drug therapy is a particular issue for 
people on fixed incomes who might be choosing between 
buying food and medications.28 Older women are less 
likely than older men to have pensions or drug benefit 
plans because they are less likely to have engaged in the 
formal work force.29 Additionally, older women are more 
likely to be caregivers and to have responsibility for 
supervising the medications for a spouse or an older 
family member.30 These caregivers need to be included in 
the medication review process. When older women 
themselves require assistance with their medications, 
they might be less likely to have a spouse or a partner to 
help provide that supervision. Further, evidence suggests 
that, compared with older men, drug therapies are 
prescribed differently to older women. For example, 
older men are even more likely than older women to 
continue receiving drug therapies often designed for 
secondary prevention at the end of life. This finding is, in 
part, because men are more likely to receive more 
aggressive medical care then women.9 This more 
aggressive care might continue even when these 
therapies are deemed to no longer be helpful and might 
actually be burdensome.9 Finally, although women are 
more likely than men to visit their health professionals, 
evidence suggests that women might be less likely to 
follow preventive guidance and to adhere to therapies.21,31,32 
This information highlights the importance of exploring 
sex and gender differences to better understand how 
interventions can be implemented to stop unnecessary 
medications and improve medication optimisation.
Figure 1 shows our suggested approach to optimising 
medication safety that clinicians can follow. This 
approach starts with the problem of polypharmacy, 
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identifies inappropriate prescribing, and uses this 
information to inform deprescribing decisions to stop 
medications, with sex and gender considered throughout.
Polypharmacy increases the risk for inappropriate 
and unsafe prescribing to older adults. Identifying 
potentially inappropriate prescribing practices (by use of 
tools and frameworks) informs judicious deprescribing 
and promotes medication safety (figure 1). Some 
tools and frameworks can help to identify inappropriate 
prescribing, and these approaches might also provide 
guidance on which drugs should be prioritised for 
deprescribing.33 Although little is known about how sex 
and gender influence polypharmacy and inappropriate 
prescribing tools or deprescribing protocols, we present 
what is known and identify the main knowledge gaps.
Polypharmacy 
Polypharmacy is generally defined as the use of five or 
more prescribed or over-the-counter drug therapies. The 
terms excessive polypharmacy and hyperpolypharmacy34 
have been used for people taking 10 or more prescription 
or over-the-counter drug therapies. Another less common 
approach to defining polypharmacy has been to use 
the terms appropriate polypharmacy or problematic 
polypharmacy. Appropriate polypharmacy recognises 
that older people might require multiple drug therapies 
to manage their complex medical conditions. Problematic 
polypharmacy35 refers to the use of multiple drug 
therapies in a way that is not appropriate—ie, the 
medications are not providing an overall benefit. This 
approach is further operationalised into hazardous drug 
combinations, unacceptable pill burden, difficulty with 
medication adherence, or when medications are being 
prescribed as part of a prescribing cascade,35 in which 
drug side-effects are misinterpreted as a new medical 
condition, leading to additional medications.
The international importance of polypharmacy was 
highlighted in WHO’s report on the Medication Without 
Harm Challenge.4 WHO’s 2019 technical statement asks 
member countries to prioritise their strong commitment 
to medication safety, identifying polypharmacy as one of 
the three action areas.36 22 countries were reported to 
have created national guidance on polypharmacy 
management.37
Although most people understand the general sense of 
the term polypharmacy, poor specificity can lead to 
confusion. One systematic review estimated that there 
are 138 different definitions of polypharmacy.38 Further, it 
is not clear if polypharmacy encompasses prescribed 
medications only or if over-the-counter drugs and other 
therapies are also included.
Given that people now live longer with multiple medical 
conditions, many older adults, particularly women, 
experience polypharmacy. Polypharmacy is particularly 
important for older women because women are more at 
risk for drug-related adverse events due to sex-related and 
gender-related considerations. Further, polypharmacy is 
associated with the prescribing of potentially inappropriate 
medications,39–41 which heightens the risk of adverse events. 
Additionally, another reason polypharmacy is a particular 
issue for women is because women make up the majority 
of long-term care residents. In 2012, among older adults 
living in long-term care homes in Europe and Israel, 
almost 50% used between five and nine daily drug 
therapies and almost a quarter used 10 or more drugs.42 For 
older adults living in long-term care homes in Canada, 
where almost 70% of residents are women,43 close to 
50% are being prescribed medications from 10 or more 
drug classes.44
Tools to identify inappropriate prescribing 
Numerous tools and frameworks are available to 
identify inappropriate prescribing and to facilitate 
deprescribing internationally. To identify inappropriate 
prescribing tools that are widely known, we selected 
those to profile by use of the list generated by the 
International Group for Reducing Inappropriate 
Medication Use and Polypharmacy (IGRIMUP)45 and 
cross-referenced them with tools included in two recent 
systematic reviews.46,47 Given the large number of these 
tools, we profiled those with 500 or more citations for 
inappropriate prescribing tools and 200 or more 
citations for deprescribing tools by use of Google 
Scholar as of January 19, 2021. For each tool, we 
identified whether sex or gender were considered. Lists 
of tools and frameworks used to identify inappropriate 
prescribing and deprescribing that met our inclusion 
criteria are shown (table). Panel 1 briefly describes each 
of the identified inappropriate prescribing tools. 
Although none of these inappropriate prescribing tools 
were developed with the consideration of sex or gender 
differences, they might have been used by other 
investigators to explore this issue. We searched Google 
Scholar for papers, using sex or gender and the name of 
the inappropriate prescribing tool or deprescribing 
process as search terms and summarised the relevant 
information.
Figure 1: Approach to optimising medication safety for older adults
Polypharmacy increases the risk for inappropriate and unsafe prescribing in older 
adults. Our suggested approach allows for the identification of potentially 
inappropriate prescribing (using tools and frameworks) and deprescribing 
processes (using the information to stop medications). Sex and gender 
considerations need to be incorporated throughout.
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The Beers criteria have been used by investigators from 
many countries, including Canada,71 Jordan,40 Sweden,41 
Switzerland,72 Brazil,39 and the USA,73 to explore how sex 
and gender might influence inappropriate prescribing. 
Most of these studies have reported that women are more 
likely than men to be prescribed medications that are 
potentially inappropriate. In Canada, Morgan and 
colleagues71 reported that 31% of women, compared with 
26% of men, filled a prescription for a potentially 
inappropriate drug therapy. This finding is primarily 
related to women being dispensed more benzodiazepine 
prescriptions than men. An earlier study among older 
veterans in the USA also reported that women were 
more likely to receive 16 of the 33 drugs on the 
inappropriate drug list, principally certain analgesics, 
psychotropic drugs, and anticholinergic agents, whereas 
men were only more likely to receive three of 33 drugs on 
the list.73 Faustino and colleagues,39 in Brazil, and 
Al-Azayzih and colleagues,40 in Jordan, also reported that 
female sex was associated with the prescription of a 
potentially inappropriate medication.
The screening tool of older persons’ prescriptions 
(STOPP) criteria have been used to evaluate inappropriate 
prescribing in primary care, in which Nuñez-Montenegro 
and colleagues74 reported that, in Spain, older women 
had a higher percentage of inappropriate prescribing 
than older men (78% vs 66%). Similarly, Wickop and 
colleagues75 reported that more medications on the 
STOPP list were prescribed to older women than men in 
Germany.
In Germany, Toepfer and colleagues76 reported that, 
although the use of potentially inappropriate medications 
was more frequent in women than in men when using 
the PRISCUS tool, the use of potentially inappropriate 
medications was associated with greater morbidity in 
men compared with that in women. Finally, a study by 
Morin and colleagues41 reported that, in Sweden, female 
sex was associated with more inappropriate drug use 
when applying the Beers criteria, PRISCUS, or the 
French consensus panel list.
Frameworks to identify inappropriate 
prescribing 
We separately identified several frameworks that were 
not included in lists of inappropriate prescribing tools 
but that were deemed as important to inform 
inappropriate prescribing by the authors. We include the 
prescribing cascade as an important framework to 
provide general guidance on drugs to be avoided or 
stopped. We also include in this category the US National 
Action Plan for Adverse Drug Event Prevention62 as an 
important reminder for those prescribing to older people 
that so-called good drugs used in inappropriate ways can 
become so-called bad drugs and cause the majority of 
adverse events.
The prescribing cascade is a framework that can be 
used to help identify an important situation when good 
drugs are used in potentially inappropriate ways. The 
prescribing cascade concept was developed by Rochon 
and Gurwitz, from Canada and the USA, respectively, 
in 199563 and updated in 2017.64 A prescribing cascade 
occurs when health-care providers misinterpret the 
side-effect of a drug as a new medical condition and 
prescribe a second drug therapy to manage this 
unrecognised drug-induced side-effect. A series of 
prescribing cascades have been identified and 
documented with large population-level data, such as 
calcium channel blockers leading to ankle oedema and 
the initiation of loop diuretic therapy.77 This framework 
applies generally to any drug therapy in which a side-
effect develops that is mistaken for a new medical 
condition and the provider responds with new drug 
treatment. In some cases, over-the-counter medications 
can be taken by the patient to manage their new medical 
condition.64 Discontinuing or reducing the dose of the 
initial drug therapy could avoid or reverse these cascades. 
The prescribing cascade has been incorporated into 
many deprescribing protocols,65,78,79 and process mapping 
can be used by clinicians to identify prescribing cascades 
in their patients.80 Further, researchers have reported 
that there are five key factors for physicians to consider 








Tools to identify inappropriate prescribing
Beers et al (1991)48 Beers criteria USA No
Fick et al (2019)49 Beers criteria USA No
Zhan et al (2001)50 Inappropriate Medication Use USA No
Bushardt et al (2008)51 Hyperpharmacotherapy assessment tool USA No
Gallagher et al (2008)52 STOPP/START criteria Ireland No
O’Mahony et al (2015)53 STOPP/START criteria Ireland No
Hanlon et al (1992)54 Medication Appropriateness Index USA No
Somers et al (2012)55 Medication Appropriateness Index Belgium No
Holt et al (2010)56 Old and venerable (PRISCUS) Germany No
McLeod et al (1997)57 Inappropriate prescribing for the elderly Canada No
Laroche et al (2007)58 French consensus panel list France No
Hilmer et al (2007)59 Drug Burden Index USA No
Rudolph et al (2008))60 Anticholinergic Risk Scale USA No
Carnahan et al (2006)61 Anticholinergic Drug Scale USA No
Frameworks to identify inappropriate prescribing
National Action Plan for 
Adverse Drug Event 
Prevention (2014)62
Good Drugs used in Inappropriate Ways USA No 
Rochon, Gurwitz (1995)63 Prescribing cascade Canada No
Rochon, Gurwitz (2017)64 Prescribing cascade USA No
Deprescribing processes
Scott et al (2015)65 The Deprescribing Protocol Australia No
Scott et al (2015)66 CEASE algorithm Australia No
Garfinkel et al (2007)67 Good Palliative–Geriatric Practice algorithm Israel No
 CEASE=current medicines, elevated risk, assess, sort, and eliminate. START=screening tool to alert doctors to the right 
treatment. STOPP=screening tool of older persons’ prescriptions.
Table: Key tools and frameworks to identify inappropriate prescribing and deprescribing processes
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with regard to prescribing cascades.81 Providing 
medication history, particularly when a medication is ed, 
would help clinicians to determine the drug prescribing 
sequence and facilitate the early recognition of a 
prescribing cascade. The iKASCADE team is currently 
studying how sex and gender influences prescribing 
cascades.82
The US National Action Plan for Adverse Drug Event 
Prevention62 describes an important way of thinking 
about medications and safety that recognises that good 
drugs when used in an unsafe or inappropriate way 
become bad. This framework builds on the work of 
Budnitz and colleagues,68 who examined emergency 
department visits for drug-related adverse events among 
older adults and reported that good drug therapies 
(eg, anticoagulants and insulin) used in inappropriate 
ways were responsible for most of these emergency room 
visits. These individual drug therapies are important 
Panel 1: Inappropriate prescribing tools
The Beers criteria48 were first created in 1991 by an expert 
consensus panel led by geriatrician Mark Beers and colleagues in 
the USA. The Beers criteria have undergone multiple updates, 
including the most recent (sixth iteration) published in 2019 
under the auspices of the American Geriatrics Society.49 The 
criteria were initially designed to assist researchers in identifying 
the quality of prescribing in long-term care homes, but these 
criteria have subsequently been applied to all clinical settings.68 
This tool provides a list of medications that are considered 
potentially inappropriate, medications to avoid in certain 
conditions, medications to use with caution, specific drug–drug 
interactions, and medications that require dose adjustment 
related to kidney function. Other researchers in the USA have 
applied the Beers criteria to generate lists of inappropriate 
medications related to community-dwelling older people50 and 
a hyperpharmacotherapy assessment tool.51
The screening tool of older persons’ prescriptions (STOPP) 
criteria were developed by O’Mahony and colleagues from 
Ireland.  These criteria were first published in 200852 and were 
updated in 201553 to include more recent drug therapies. This 
tool was created by a group of experts who identified drug 
therapies that were potentially inappropriate for older people, 
organised by physiological system. This tool includes drug 
therapies in which there are drug–drug interactions and 
duplications of drugs within a class. The screening tool of older 
persons’ prescriptions in frail adults with limited life expectancy 
(STOPPFrail) criteria,69 which are partly based on the STOPP/
screening tool to alert doctors to the right treatment (START) 
criteria,53 were developed in Ireland and first published in 2017. 
This tool provides a list of potentially inappropriate drug 
therapies that should be discontinued in older adults who have 
all of the following characteristics: “end stage irreversible 
pathology, poor one-year survival prognosis, severe functional 
impairment or severe cognitive impairment or both, [in whom] 
symptom control is the priority rather than prevention of 
disease progression”.69 This tool has also been assessed for use 
at end of life among people who are hospitalised. The second 
iteration of the STOPPFrail criteria was published in 2021.70
In 1992, the Medication Appropriateness Index was created by 
Hanlon and colleagues54 in the USA. In 2012, this tool was 
adapted by Somers and colleagues55 in Belgium. The original 
Medication Appropriateness Index provides a list of 
10 questions that must be addressed to identify potential 
drug-related problems associated with a specific medication. 
For each question, a rating from 1 to 3 is given, to indicate in 
some cases the degree to which the medication is indicated or 
not, or whether the directions are practical or impractical. 
A strength of this tool is that it assesses a range of issues that 
are important to consider when evaluating the ongoing need 
for a medication and it can be used to assess a variety of 
medications. 
The PRISCUS criteria were developed in 2010 by an expert 
consensus panel through a modified Delphi process, led by 
Stefanie Holt and colleagues,56 in Germany. This list of potentially 
inappropriate medications was developed for informing safer 
medication use among the older adult population and was 
specifically tailored for the German pharmaceutical market. 
Alongside a list of potentially inappropriate medications, details 
addressed also included the associated main concerns, possible 
therapeutic alternatives, and precautions to be taken when these 
medications cannot be avoided.56
The inappropriate prescribing for the elderly tool is a 
consensus-based list first developed in 1997, led by McLeod and 
colleagues57 in Canada. This list identifies inappropriate 
practices in prescribing for older people that are included in 
three categories: drugs generally contraindicated for older 
people, drug–disease interactions, and drug–drug interactions. 
Along with the clinical importance of the risk, suggestions for 
alternative therapies that might be equally or more effective 
and less risky were included.57
The French consensus panel list was developed in 2007 by an 
expert consensus panel through a two-round Delphi method, 
led by Marie-Laure Laroche and colleagues58 in France. This list 
of potentially inappropriate medications was developed for 
safer medication use among the French population aged 
75 years and older. The tool provides a list of criteria along with 
the reasons for concern and possible alternative drugs.58
Another tool that has been developed specifically to assess 
pharmacological risk is the Drug Burden Index, led by Hilmer 
and colleagues59 (from the USA), which is used to assess the 
burden of anticholinergic and sedative medications. Further 
tools include the Anticholinergic Risk Scale, developed by 
Rudolph and colleagues60 (from the USA) and the 
Anticholinergic Drug Scale, developed by Carnahan61 (from the 
USA), which are used to assess the burden and risk of adverse 
events associated with the use of anticholinergic drugs. None of 
these tools take sex or gender into consideration.
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because they each have narrow therapeutic windows. 
This study identified the essential need for interventions 
to improve the prescribing of good drugs used in 
inappropriate ways, to reduce adverse events leading to 
excess emergency department visits among older adults. 
For example, to prevent these problems there needs to be 
timely intervention when a patient’s clinical situation 
changes. These interventions might include dose 
reduction or discontinuation, even in some cases on a 
temporary basis, and involve working closely with 
patients and their care providers.
The deprescribing process: tools and protocols 
Deprescribing is defined as the “systematic process of 
identifying and discontinuing drugs in instances in 
which existing or potential harms outweigh existing or 
potential benefits within the context of an individual 
patient’s care goals, current level of functioning, life 
expectancy, values and preferences”.65 The term 
“deprescribing” was first used by Michael Woodward 
in 200383 and has since gained traction and popularity 
because it provides a call-to-action to consider when and 
how to stop a medicine that might be inappropriate for 
the patient’s clinical status and prognosis.
Reducing inappropriate medication use, specifically 
among older adults, has been linked to decreases in 
falls,84 confusion,85 and emergency room visits.68 Although 
there is a great deal of support for deprescribing by 
clinicians and patients internationally, a systematic 
review of the literature has not shown the benefit of 
deprescribing on hospital admission or mortality.86
Given the magnitude of overprescribing in older adults, 
deprescribing initiatives have been developed at an 
international level (IGRIMUP)45 and national level in 
several countries, including Canada, the USA, and 
Australia, as a means to reduce excessive doses or to 
discontinue inappropriate drug therapy. A narrative 
review conducted by Reeve87 categorises the available 
types of deprescribing tools, including those that provide 
general deprescribing guidance, those that are drug-
specific, tools for identi fying potentially inappropriate 
medications (table), and those that are designed to 
engage patient participation. Tools developed to identify 
inappropriate medications can directly inform 
deprescribing and the deprescribing processes and often 
use inappropriate medication tools as one of their steps. 
Some deprescribing processes have been developed for 
use in key life stages in which it is important to reconsider 
the ongoing benefit of medications, such as when an 
individual’s goals of care change because they become 
frail, develop cognitive impairment, or are approaching 
the end of their life.67 Two of the most widely cited 
deprescribing protocols are described (panel 2). Neither 
of these protocols mention sex or gender.
Despite the importance of deprescribing and the 
evidence that older women experience more drug-related 
adverse events, to our knowledge, only one study has 
explored gender differences in the deprescribing process. 
This study showed that women were more aware of 
harmful medications and were more likely than men to 
initiate a deprescribing conversation and to seek out 
medication-induced harm.90
Implications of deprescribing in clinical practice 
Deprescribing a medication is not always easy 
Judicious deprescribing of a medication can be 
challenging and is not always successful. There are 
several barriers to stopping medications. Whether 
justified or not, prescribers might be more concerned 
about harm caused by stopping a medication than by the 
potential harm associated with continuing a medication 
of questionable benefit that is being tolerated.91 This 
concern might, in part, be due to the dearth of evidence 
to support deprescribing of a specific drug in older 
people. The attitude of older patients themselves towards 
deprescribing is crucial for success. A population-based 
survey in the USA reported that older adults are willing 
to having their medications deprescribed if their 
provider says this is possible. Further, two-thirds of 
patients want to take fewer medicines,92 indicating that 
there is support for deprescribing from older people. 
There are also differences between men and women 
when considering awareness of harmful medications 
Panel 2: Deprescribing tool
The deprescribing protocol is a five-step approach that was published by Scott and 
colleagues65 (from Australia) in 2015. The CEASE algorithm describes the approach used in 
the following order: current medicines, elevated risk, assess, sort, and eliminate.66 Scott 
has also created an algorithm for deciding the order and the mode in which a drug 
therapy could be discontinued.65 This approach identifies each medication the individual 
is taking and the reasons for them, considers the overall risk of drug-induced harm, 
assesses each drug for its eligibility to be discontinued, prioritises the drugs for 
discontinuation, and implements and monitors the drug discontinuation regimen.65
The Good Palliative–Geriatric Practice algorithm was developed in 2007 by Garfinkel and 
colleagues67 in Israel, and is designed to address the problem of polypharmacy. This 
approach requires a discussion with the patient or their caregiver. Further, the approach 
uses a series of questions to guide the process of stopping a drug therapy, decreasing the 
dose, or shifting to an alternative drug therapy, as appropriate. This approach can lead to 
discontinuing multiple non-lifesaving drugs in older people and incorporates an 
individual’s circumstances, their goals of care, and ongoing monitoring. In relation to 
deprescribing, Garfinkel places particular emphasis on the need to focus on patients 
described as being of VOCODFLEX status (ie, very old age, the extent of comorbidity, 
dementia, frailty and limited life expectancy).88 This deprescribing process has been 
evaluated in geriatric nursing departments and nursing homes,67 and among older people 
in the community.67,89 The tool was used to inform deprescribing and evaluated in disabled 
patients in a nursing home setting.67 On average, approximately 3 drugs were 
discontinued per individual resident. The discontinuation of medications reduced 
mortality and improved quality of life. In the study of community-dwelling older adults, 
among those medications discontinued using the deprescribing algorithm, only 6 (2%) of 
the 256 discontinued medications in 64 patients were restarted due to the reoccurrence 
of the original indication, with 56 (88%) of the 64 patients reporting overall improved 
health.89
For more on deprescribing in 
Canada see https://www.
deprescribingnetwork.ca/
For more on deprescribing in 
the USA see https://
deprescribingresearch.org/
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and willingness to initiate deprescribing conversations.90 
Stopping medications requires time that might not be 
readily available to prescribers in the current health 
system. Clinic visits are generally short and, given that 
these visits often last only 15–20 min, it is easier for 
physicians to continue medicines that appear to be 
tolerated rather than stopping them.93 When deciding 
whether to discontinue a medication, it is important to 
understand when and why it was started. Yet, this 
information might be difficult or sometimes impossible 
to obtain from existing medical records. These problems 
might be increased for older people, given that some 
drugs might have been started many years ago and 
medical records might not be readily available. 
Additionally, when older adults are admitted to hospital, 
chronic care facilities, and long-term care settings, 
medical records across the health-care system might not 
be coordinated. Thus, information about why new drugs 
were initiated might not be provided back to the primary 
care provider.93 Moreover, primary care providers might 
be reluctant to modify drugs prescribed by a different 
specialist.
Despite the challenges, the benefits of deprescribing 
could be considerable, as shown with antipsychotic drug 
therapy. Antipsychotic therapy has long been associated 
with serious adverse events, including death.94 Initiatives 
have reduced the use of antipsychotic therapy for 
dementia management in long-term care homes by 
leveraging non-pharmacological approaches95 without 
increasing behavioural or psychotic symptoms. Among 
people with Alzheimer’s dementia receiving risperidone, 
for every four patients whose risperidone was withdrawn, 
one relapsed with the symptoms of psychosis or 
agitation,93,96 showing that deprescribing is an iterative 
process and will not be successful for all. Recognising 
the challenges with deprescribing, the deprescribing 
algorithm created by Scott acknowledges that this process 
might not be successful and that there might be a need to 
restart treatment with the drug in question.65
Practical approach to deprescribing that clinicians can 
apply to the patient in front of them 
Because many older adults, particularly women, are in 
need of deprescribing, we propose that older adults 
experiencing polypharmacy (defined as the use of 
five or more concurrent drug therapies) should be 
initially screened for judicious deprescribing. In older 
patients with polypharmacy, it is important to identify 
potentially inappropriate medications with the use of 
established tools. Then, the deprescribing process can 
be initiated. Deprescribing protocols generally consider 
the key conditions that influence the need for 
deprescribing decisions for older people, specifically 
frailty, declining cognitive function, and limited 
remaining life.97 Accordingly, we have created the 
DRUGS guide to optimising medication safety for older 
adults, which stands for DISCUSS goals of care and 
what matters most, REVIEW medications, USE tools 
and frameworks, GERIATRIC medicine approach, and 
STOP the medications where appropriate (figure 2). For 
each of the five steps, we provide sex and gender 
considerations. This approach was based on our 
collective expertise as eight geriatricians and 
researchers with a background in geriatric 
pharmacology from six countries (Belgium, Canada, 
Ireland, Israel, Italy, and the USA) working together on 
iKASCADE, an international initiative designed to 
improve prescribing for older women and men.82 This 
guide is based on the approach generally used by 
geriatricians, is consistent with the recommendations 
outlined in our previous publications on optimising 
prescribing for older adults,33,98,99 and aligned with the 
approach described by Scott.65
Figure 2: DRUGS guide to optimising medication safety for older adults
Five DRUGS steps created by eight geriatricians to guide the optimisation of medication safety are outlined: 
(1) DISCUSS goals of care and what matters most, (2) REVIEW medications, (3) USE tools and frameworks, 
(4) GERIATRIC medicine approach, and (5) STOP the medications. Each of the five steps are shown with examples 
of sex and gender considerations. STOPP=screening tool of older persons’ prescriptions. STOPPFrail=screening tool 
of older persons’ prescriptions in frail adults with limited life expectancy.






DISCUSS goals of care and what matters most to the patient 
• Include patients and caregivers in deprescribing discussions to ensure
decisions focus on goals of care
REVIEW medications
• Encourage patients to bring all prescribed and over-the-counter
medications to their appointment
• Review medications on an ongoing basis and when clinical conditions
or goals of care change
• Discontinue potentially unnecessary drugs
• Consider drug side-effects as a potential cause for a new symptom
• Consider non-pharmacological options
• Change for safer alternatives
• Lower the dose
• To identify possible prescribing cascades, determine when the 
medication was started and why
USE tools and frameworks
• Identify drugs from the inappropriate prescribing tools, including 
Beers criteria or STOPP criteria
• Use the STOPPFrail list when the individual is extremely frail and
approaching the end of life
• Consider whether the new or existing medical condition could be 
the result of a prescribing cascade and ask:
• Is a new drug being prescribed to manage a side-effect from another 
prescribed drug?
• Could the initial drug be replaced with a safer drug or could the dose 
be reduced?
• Does the patient need the first drug or could this drug be stopped?
• Pay attention to older people who are receiving so-called good drugs 
with narrow therapeutic windows that might no longer be needed 
or for whom dose reduction might be beneficial
GERIATRIC medicine approach
• Geriatricians carefully consider how multiple medical problems, 
frailty, cognitive impairment, and limited life expectancy reduce 
medication benefit, increase adverse events, or interfere with 
medication adherence
STOP the medications
• Consider the algorithm created by Scott⁶⁵ or the Good 
Palliative–Geriatric Practice algorithm to guide deprescribing
Women are more likely than men to 
be caregivers, and might not have a 
caregiver to advocate for them
Women use more prescribed and 
over-the-counter medications than
men
Women are more often prescribed 
psychoactive drugs, whereas men 
are more often prescribed secondary 
prevention drugs; women might 
require lower doses; men receive 
more aggressive medical therapy
Women are more likely than men to 
have multiple medical problems, 
frailty, and adverse drug events; 
men are more likely than women to 
adhere to drug therapies; women 
might be less able than men to pay 
for medicines, decreasing adherence 
Women are more likely to discuss 
deprescribing with providers than 
men
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Gaps and needs 
Our exploration of polypharmacy, tools, and frameworks 
to identify inappropriate prescribing and deprescribing 
processes for older women and men has identified 
certain gaps in knowledge-based practice. In reviewing 
the key descriptions of polypharmacy, tools and 
frameworks to reduce inappropriate prescribing, and 
deprescribing protocols, it is remarkable that none of 
these tools and frameworks mention clinically 
important differences between women and men (table). 
Although women make up the majority of older people 
and are more vulnerable than men to drug-related 
harm, existing research has almost completely 
neglected this consideration. The solutions offered in 
this Review will require a consideration of sex and 
gender, alongside age, in all drug research, from early 
clinical trials through to postmarketing surveillance.13 
These considerations will inform the current under-
standing of polypharmacy, improve the development of 
future tools and frameworks to identify inappropriate 
prescribing, and guide geriatric medicine-informed 
deprescribing protocols.
Conclusion 
Improving prescribing for older adults is an 
international priority for all health-care systems. The 
approach of geriatric medicine to polypharmacy is one 
that carefully considers the goals of care of an older 
person. Although polypharmacy is a major problem, 
there are tools and frameworks that identify 
inappropriate prescribing and deprescribing protocols 
that provide guidance to judiciously decrease doses and 
stop unneces sary medications. Our DRUGS guide to 
deprescribing, created by eight geriatricians with a 
background in geriatric pharmacology, provides 
five simple steps to stop inappropriate drug therapy. 
Further research needs to consider the potentially 
important influence of sex and gender on inappropriate 
prescribing and deprescribing to optimise medication 
safety.
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